NSTL国家科技图书文献中心

1. HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy NSTL国家科技图书文献中心

Liu, Jian | Zhang, Xiaofeng ... - 《International Journal of Cancer》 - 2025,156(6) - 1293～1303 - 共11页

摘要： undergoing antiviral* therapy (AVT). Data of 949 consecutive* | Serum hepatitis B core-related antigen (HBcrAg | ) is considered a surrogate marker of the amount and | activity of intrahepatic covalently closed circular DNA | . This study aimed to explore the prognostic value of

关键词： antiviral therapy | hepatitis B core-related antigen | hepatocellular carcinoma | overall survival | recurrence | hepatitis B core‐related antigen

2. DAA‐PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy NSTL国家科技图书文献中心

Amit G. Singal | K. Rajender Reddy ... - 《Journal of viral hepatitis.》 - 2025,32(2) - e14056～e14056 - 共4页

摘要：ABSTRACT Direct‐acting antiviral (DAA) therapy | recurrence following DAA therapy. DAA‐PASS was a | therapy exposure during routine clinical care. Eligible | enrolled, 24 were treated with DAA therapy. Ten HCC | recurrence associated with DAA therapy* was 0.6 (95% CI, 0.2*

关键词： cancer recurrence | Direct‐acting antiviral | hepatitis C virus | hepatocellular carcinoma

3. Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy NSTL国家科技图书文献中心

Chu, Yu-De | Hsu, Chao-Wei ... - 《Journal of gastroenterology and hepatology》 - 2025,40(1) - 265～273 - 共9页

摘要： finite course of nucleoside analog (NA) therapy | genes during finite NA therapy* has not been carefully* | finite antiviral* therapies. Pre-existing surface* | Background and AimHepatitis B virus (HBV | ) reactivation could develop after withdrawal following a

关键词： deep sequencing | entecavir | quasispecies | reverse transcriptase | surface antigen escape mutant | tenofovir disoproxil fumarate

4. Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy NSTL国家科技图书文献中心

Yao, Bilian | Xu, Qi ... - 《Antiviral Research》 - 2025,234 - 106077～106077 - 共9页

摘要： decreased after antiviral* therapy. Both O-glycosylated* | ETV therapy. O-glycosylated HBsAg was significantly | patients after Peg-IFN alpha therapy* compared to that of* | HBsAg level decreased during anti-viral therapy* and* | Background: Recent evidence has indicated that

关键词： Hepatitis B virusB surface antigen | O -glycosylated HBsAg | HBV RNA

5. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy NSTL国家科技图书文献中心

Tahata, Yuki | Hikita, Hayato ... - 《Hepatology research》 - 2025,55(3) - 319～332 - 共14页

摘要： cirrhosis, after direct-acting antiviral* therapy are* | -acting antiviral* therapy.* | cirrhosis patients treated with direct-acting antiviral | therapy from February 2019 to December 2021 at 33 | AimThe incidence of and factors involved in

关键词： DAA | esophagogastric varix | HCV | sustained virologic response | varix aggravation | varix rupture

6. Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy NSTL国家科技图书文献中心

Pfaeffle,M. | Duenkelmann,S.... - 《Infection》 - 2025,53(3) - 1205～1211 - 共7页

摘要： revolutionized by introduction of direct-acting antiviral | therapy (DAA). Short treatment duration of eight to | substitution therapy* (OST).Methods All PWID or on OST* | receiving DAA therapy* between 3/2021–11/2022 at an* | prescriptions for the full length of therapy, while patients

关键词： HCV | PWID | DAA | Adherence

7. Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy NSTL国家科技图书文献中心

Loo, Yan Shan | Yusoh, Nur Aininie ... - 《Nanomedicine》 - 2025,20(3/4) - 401～416 - 共16页

摘要： phytochemicals for antiviral* application, highlighting their* | demonstrated antiviral* mechanisms. It specifically examines* | the antiviral* activities of phytochemical-loaded* | these nanosystems in photodynamic therapy* (PDT* | Phytochemicals are typically natural bioactive

关键词： Phytochemical | nanoparticles | virus | infection | antiviral | photodynamic therapy

8. Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy NSTL国家科技图书文献中心

Tsai, Ying-Nan | Lo, Jamie Chieh ... - 《Journal of viral hepatitis.》 - 2025,32(1) - e14047～e14047 - 共8页

摘要： differ according to the type of therapy* used. This is a* | Hepatitis C virus (HCV) infection is | associated with a myriad of extrahepatic manifestations | (EHM), as well as the production of autoantibodies | , including rheumatoid factor (RF). This study aims to

关键词： direct‐acting antivirals | extrahepatic manifestations | hepatitis C | interferon | rheumatoid factor | direct-acting antivirals

9. Outcomes of CMV infection in the setting of gastrointestinal graft-vs.-host disease in the era of pre-emptive and prophylactic antiviral therapy NSTL国家科技图书文献中心

Patel, Meera | Singh, Supriya ... - 《Transplant immunology》 - 2025,90 - 102232～102232 - 共5页

摘要： prophylactic antiviral* therapy.* | prophylaxis with letermovir therapy* has been shown to* | the use of letermovir therapy* for CMV prophylaxis in* | letermovir therapy* for primary CMV prophylaxis, and 7 of* | better assess the impact of letermovir therapy* on*

关键词： CMVi (cytomegalovirus infection) | GI-GVHD (Gastrointestinal graft vs. host | disease) | Allo-HCT (allogenic hematopoietic cell | transplantation)

10. A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B NSTL国家科技图书文献中心

Ha, Yeonjung | Lee, Seungseok ... - 《Liver international》 - 2025,45(4) - e16139～e16139 - 共12页

摘要： entecavir (ETV) or tenofovir (TFV) therapy. Methods: CHB | diagnosed with HCC during the first 5 years of therapy | , cirrhosis, and type of antiviral* agent) and laboratory* | therapy and, therefore, could facilitate individualised | Background and aims: This study aims to

摘要： undergoing antiviral* therapy (AVT). Data of 949 consecutive* | Serum hepatitis B core-related antigen (HBcrAg | ) is considered a surrogate marker of the amount and | activity of intrahepatic covalently closed circular DNA | . This study aimed to explore the prognostic value of

关键词： antiviral therapy | hepatitis B core-related antigen | hepatocellular carcinoma | overall survival | recurrence | hepatitis B core‐related antigen

摘要：ABSTRACT Direct‐acting antiviral (DAA) therapy | recurrence following DAA therapy. DAA‐PASS was a | therapy exposure during routine clinical care. Eligible | enrolled, 24 were treated with DAA therapy. Ten HCC | recurrence associated with DAA therapy* was 0.6 (95% CI, 0.2*

关键词： cancer recurrence | Direct‐acting antiviral | hepatitis C virus | hepatocellular carcinoma

摘要： finite course of nucleoside analog (NA) therapy | genes during finite NA therapy* has not been carefully* | finite antiviral* therapies. Pre-existing surface* | Background and AimHepatitis B virus (HBV | ) reactivation could develop after withdrawal following a

关键词： deep sequencing | entecavir | quasispecies | reverse transcriptase | surface antigen escape mutant | tenofovir disoproxil fumarate

摘要： decreased after antiviral* therapy. Both O-glycosylated* | ETV therapy. O-glycosylated HBsAg was significantly | patients after Peg-IFN alpha therapy* compared to that of* | HBsAg level decreased during anti-viral therapy* and* | Background: Recent evidence has indicated that

关键词： Hepatitis B virusB surface antigen | O -glycosylated HBsAg | HBV RNA

摘要： cirrhosis, after direct-acting antiviral* therapy are* | -acting antiviral* therapy.* | cirrhosis patients treated with direct-acting antiviral | therapy from February 2019 to December 2021 at 33 | AimThe incidence of and factors involved in

关键词： DAA | esophagogastric varix | HCV | sustained virologic response | varix aggravation | varix rupture

摘要： revolutionized by introduction of direct-acting antiviral | therapy (DAA). Short treatment duration of eight to | substitution therapy* (OST).Methods All PWID or on OST* | receiving DAA therapy* between 3/2021–11/2022 at an* | prescriptions for the full length of therapy, while patients

关键词： HCV | PWID | DAA | Adherence

摘要： phytochemicals for antiviral* application, highlighting their* | demonstrated antiviral* mechanisms. It specifically examines* | the antiviral* activities of phytochemical-loaded* | these nanosystems in photodynamic therapy* (PDT* | Phytochemicals are typically natural bioactive

关键词： Phytochemical | nanoparticles | virus | infection | antiviral | photodynamic therapy

摘要： differ according to the type of therapy* used. This is a* | Hepatitis C virus (HCV) infection is | associated with a myriad of extrahepatic manifestations | (EHM), as well as the production of autoantibodies | , including rheumatoid factor (RF). This study aims to

关键词： direct‐acting antivirals | extrahepatic manifestations | hepatitis C | interferon | rheumatoid factor | direct-acting antivirals

摘要： prophylactic antiviral* therapy.* | prophylaxis with letermovir therapy* has been shown to* | the use of letermovir therapy* for CMV prophylaxis in* | letermovir therapy* for primary CMV prophylaxis, and 7 of* | better assess the impact of letermovir therapy* on*

关键词： CMVi (cytomegalovirus infection) | GI-GVHD (Gastrointestinal graft vs. host | disease) | Allo-HCT (allogenic hematopoietic cell | transplantation)

摘要： entecavir (ETV) or tenofovir (TFV) therapy. Methods: CHB | diagnosed with HCC during the first 5 years of therapy | , cirrhosis, and type of antiviral* agent) and laboratory* | therapy and, therefore, could facilitate individualised | Background and aims: This study aims to

关键词： chronic hepatitis B | hepatocellular carcinoma | machine learning | prediction | validation

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： undergoing antiviral therapy (AVT). Data of 949 consecutive | Serum hepatitis B core-related antigen (HBcrAg | ) is considered a surrogate marker of the amount and | activity of intrahepatic covalently closed circular DNA | . This study aimed to explore the prognostic value of

关键词： antiviral therapy | hepatitis B core-related antigen | hepatocellular carcinoma | overall survival | recurrence | hepatitis B core‐related antigen

摘要：ABSTRACT Direct‐acting antiviral (DAA) therapy | recurrence following DAA therapy. DAA‐PASS was a | therapy exposure during routine clinical care. Eligible | enrolled, 24 were treated with DAA therapy. Ten HCC | recurrence associated with DAA therapy was 0.6 (95% CI, 0.2

关键词： cancer recurrence | Direct‐acting antiviral | hepatitis C virus | hepatocellular carcinoma

摘要： finite course of nucleoside analog (NA) therapy | genes during finite NA therapy has not been carefully | finite antiviral therapies. Pre-existing surface | Background and AimHepatitis B virus (HBV | ) reactivation could develop after withdrawal following a

关键词： deep sequencing | entecavir | quasispecies | reverse transcriptase | surface antigen escape mutant | tenofovir disoproxil fumarate

摘要： decreased after antiviral therapy. Both O-glycosylated | ETV therapy. O-glycosylated HBsAg was significantly | patients after Peg-IFN alpha therapy compared to that of | HBsAg level decreased during anti-viral therapy and | Background: Recent evidence has indicated that

关键词： Hepatitis B virusB surface antigen | O -glycosylated HBsAg | HBV RNA

摘要： cirrhosis, after direct-acting antiviral therapy are | -acting antiviral therapy. | cirrhosis patients treated with direct-acting antiviral | therapy from February 2019 to December 2021 at 33 | AimThe incidence of and factors involved in

关键词： DAA | esophagogastric varix | HCV | sustained virologic response | varix aggravation | varix rupture

摘要： revolutionized by introduction of direct-acting antiviral | therapy (DAA). Short treatment duration of eight to | substitution therapy (OST).Methods All PWID or on OST | receiving DAA therapy between 3/2021–11/2022 at an | prescriptions for the full length of therapy, while patients

关键词： HCV | PWID | DAA | Adherence

摘要： phytochemicals for antiviral application, highlighting their | demonstrated antiviral mechanisms. It specifically examines | the antiviral activities of phytochemical-loaded | these nanosystems in photodynamic therapy (PDT | Phytochemicals are typically natural bioactive

关键词： Phytochemical | nanoparticles | virus | infection | antiviral | photodynamic therapy

摘要： differ according to the type of therapy used. This is a | Hepatitis C virus (HCV) infection is | associated with a myriad of extrahepatic manifestations | (EHM), as well as the production of autoantibodies | , including rheumatoid factor (RF). This study aims to

关键词： direct‐acting antivirals | extrahepatic manifestations | hepatitis C | interferon | rheumatoid factor | direct-acting antivirals

摘要： prophylactic antiviral therapy. | prophylaxis with letermovir therapy has been shown to | the use of letermovir therapy for CMV prophylaxis in | letermovir therapy for primary CMV prophylaxis, and 7 of | better assess the impact of letermovir therapy on

关键词： CMVi (cytomegalovirus infection) | GI-GVHD (Gastrointestinal graft vs. host | disease) | Allo-HCT (allogenic hematopoietic cell | transplantation)

摘要： entecavir (ETV) or tenofovir (TFV) therapy. Methods: CHB | diagnosed with HCC during the first 5 years of therapy | , cirrhosis, and type of antiviral agent) and laboratory | therapy and, therefore, could facilitate individualised | Background and aims: This study aims to

关键词： chronic hepatitis B | hepatocellular carcinoma | machine learning | prediction | validation

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： undergoing antiviral* therapy (AVT). Data of 949 consecutive* | Serum hepatitis B core-related antigen (HBcrAg | ) is considered a surrogate marker of the amount and | activity of intrahepatic covalently closed circular DNA | . This study aimed to explore the prognostic value of

摘要：ABSTRACT Direct‐acting antiviral (DAA) therapy | recurrence following DAA therapy. DAA‐PASS was a | therapy exposure during routine clinical care. Eligible | enrolled, 24 were treated with DAA therapy. Ten HCC | recurrence associated with DAA therapy* was 0.6 (95% CI, 0.2*

摘要： finite course of nucleoside analog (NA) therapy | genes during finite NA therapy* has not been carefully* | finite antiviral* therapies. Pre-existing surface* | Background and AimHepatitis B virus (HBV | ) reactivation could develop after withdrawal following a

摘要： decreased after antiviral* therapy. Both O-glycosylated* | ETV therapy. O-glycosylated HBsAg was significantly | patients after Peg-IFN alpha therapy* compared to that of* | HBsAg level decreased during anti-viral therapy* and* | Background: Recent evidence has indicated that

摘要： cirrhosis, after direct-acting antiviral* therapy are* | -acting antiviral* therapy.* | cirrhosis patients treated with direct-acting antiviral | therapy from February 2019 to December 2021 at 33 | AimThe incidence of and factors involved in

摘要： revolutionized by introduction of direct-acting antiviral | therapy (DAA). Short treatment duration of eight to | substitution therapy* (OST).Methods All PWID or on OST* | receiving DAA therapy* between 3/2021–11/2022 at an* | prescriptions for the full length of therapy, while patients

摘要： phytochemicals for antiviral* application, highlighting their* | demonstrated antiviral* mechanisms. It specifically examines* | the antiviral* activities of phytochemical-loaded* | these nanosystems in photodynamic therapy* (PDT* | Phytochemicals are typically natural bioactive

摘要： differ according to the type of therapy* used. This is a* | Hepatitis C virus (HCV) infection is | associated with a myriad of extrahepatic manifestations | (EHM), as well as the production of autoantibodies | , including rheumatoid factor (RF). This study aims to

摘要： prophylactic antiviral* therapy.* | prophylaxis with letermovir therapy* has been shown to* | the use of letermovir therapy* for CMV prophylaxis in* | letermovir therapy* for primary CMV prophylaxis, and 7 of* | better assess the impact of letermovir therapy* on*

摘要： entecavir (ETV) or tenofovir (TFV) therapy. Methods: CHB | diagnosed with HCC during the first 5 years of therapy | , cirrhosis, and type of antiviral* agent) and laboratory* | therapy and, therefore, could facilitate individualised | Background and aims: This study aims to